Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27823942 | 1.00 | NLRP3 (0.39) | NLRP3JAK2JAK1TYK2JAK3 | |
| SCHEMBL5115899 | 1.00 | NLRP3 (0.39) | NLRP3JAK2JAK1TYK2JAK3 | |
| SCHEMBL5696892 | 0.91 | ALDH1A1 (0.43) | NLRP3JAK2JAK1TYK2JAK3 | |
| SCHEMBL6256094 | 0.91 | — | — | |
| SCHEMBL17029138 | 0.91 | ALDH1A1 (0.43) | NLRP3JAK2JAK1TYK2JAK3 | |
| Hydrochloric Acid SCHEMBL28064641 | 0.89 | — | — | |
| SCHEMBL27803270 | 0.88 | NLRP3 (0.37) | NLRP3JAK2JAK1TYK2JAK3 | |
| SCHEMBL27823944 | 0.88 | NLRP3 (0.37) | NLRP3JAK2JAK1TYK2JAK3 | |
| SCHEMBL27803271 | 0.88 | NLRP3 (0.37) | NLRP3JAK2JAK1TYK2JAK3 | |
| SCHEMBL7186641 | 0.83 | LMNA (0.37) | NLRP3JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593202-B2 | Polycarbonate resin composition pellets and process for manufacturing same | IDEMITSU KOSAN CO., LTD. (JP) | 2017-03-14 | — | — | US | disclosed |
| CN-102947310-B | Fused pyridine compounds as dual modulators of the 5-HT2A and D3 receptors | HOFFMAN-LA ROCHE LTD. (CH) | 2015-11-25 | — | — | CN | disclosed |
| US-20140364546-A1 | POLYCARBONATE RESIN COMPOSITION PELLETS AND PROCESS FOR MANUFACTURING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8816090-B2 | Benzisoxazole derivatives | PFIZER INC. (US) | 2014-08-26 | — | — | US | disclosed |
| EP-1856114-B1 | BENZISOXAZOLE DERIVATIVES | PFIZER (US) | 2014-08-20 | — | — | EP | disclosed |
| CN-102947310-A | Fused pyridine compounds as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN LA ROCHE | 2013-02-27 | — | — | CN | disclosed |
| CN-101778820-B | Benzoyl-piperidine derivatives as dual modulators of the 5-ht2a and d3 receptors | HOFFMANN LA ROCHE | 2012-12-05 | — | — | CN | disclosed |
| CN-102471276-A | Novel tetrahydroisoquinoline compounds | DAIICHI SANKYO CO LTD | 2012-05-23 | — | — | CN | disclosed |
| CN-102164914-A | Benzo[d]isoxazol-3-yl-piperazin derivatives useful as modulators of dopamine D3 receptors | HOFFMANN LA ROCHE | 2011-08-24 | — | — | CN | disclosed |
| CN-102159557-A | Piperazine d3 and 5-ht2a receptor modulators | HOFFMANN LA ROCHE | 2011-08-17 | — | — | CN | disclosed |
| CN-101981012-A | Novel tetrahydroisoquinoline derivative | DAIICHI SANKYO CO LTD | 2011-02-23 | — | — | CN | disclosed |
| CN-101778820-A | Benzoyl-piperidine derivatives as dual modulators of the 5-ht2a and d3 receptors | HOFFMANN LA ROCHE | 2010-07-14 | — | — | CN | disclosed |
| US-20080207690-A1 | Benzisoxazole Derivatives | RAQUALIA PHARMA INC. (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20070037906-A1 | Polycarbonate resin composition and optical part | IDEMITSU KOSAN CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-6090950-A | Chiral hydride complexes | ZEELAND CHEMICALS, INC. (US) | 2000-07-18 | — | — | US | disclosed |
| WO-1998007653-A1 | CHIRAL HYDRIDE COMPLEXES | ZEELAND CHEMICALS, INC. (US) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207690-A1 | Benzisoxazole Derivatives | BRS3, MRGPRX4, HTR4 | NLRP3 1135/4885JAK2 1247/4885JAK1 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.